Literature DB >> 18239032

Inhibition of rho family functions by lovastatin promotes myelin repair in ameliorating experimental autoimmune encephalomyelitis.

Ajaib Singh Paintlia1, Manjeet Kaur Paintlia, Avtar Kaur Singh, Inderjit Singh.   

Abstract

Impaired remyelination is critical to neuroinflammation in multiple sclerosis (MS), which causes chronic and relapsing neurological impairments. Recent studies revealed that immunomodulatory activity of statins in an experimental autoimmune encephalomyelitis (EAE) model of MS are via depletion of isoprenoids (farnesyl-pyrophosphate and geranylgeranyl-pyrophosphate) rather than cholesterol in immune cells. In addition, we previously documented that lovastatin impedes demyelination and promotes myelin repair in treated EAE animals. To this end, we revealed the underlying mechanism of lovastatin-induced myelin repair in EAE using in vitro and in vivo approaches. Survival, proliferation (chondroitin sulfate proteoglycan-NG2(+) and late oligodendrocyte progenitor marker(+)), and terminal-differentiation (myelin basic protein(+)) of OPs was significantly increased in association with induction of a promyelinating milieu by lovastatin in mixed glial cultures stimulated with proinflammatory cytokines. Lovastatin-induced effects were reversed by cotreatment with mevalonolactone or geranylgeranyl-pyrophosphate, but not by farnesyl-pyrophosphate or cholesterol, suggesting that depletion of geranygeranyl-pyrophosphate is more critical than farnesyl-pyrophosphate in glial cells. These effects of lovastatin were mimicked by inhibitors of geranylgeranyl-transferase (geranylgeranyl transferase inhibitor-298) and downstream effectors {i.e., Rho-family functions (C3-exoenzyme) and Rho kinase [Y27632 (N-(4-pyridyl)-4-(1-aminoethyl)cyclohexanecarboxamide dihydrochloride)]} but not by an inhibitor of farnesyl-transferase (farnesyl transferase inhibitor-277). Moreover, activities of Rho/Ras family GTPases were reduced by lovastatin in glial cells. Corresponding with these findings, EAE animals exhibiting demyelination (on peak clinical day; clinical scores >/=3.0) when treated with lovastatin and aforementioned agents validated these in vitro findings. Together, these data provide unprecedented evidence that-like immune cells-geranylgeranyl-pyrophosphate depletion and thus inhibition of Rho family functions in glial cells by lovastatin promotes myelin repair in ameliorating EAE.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18239032      PMCID: PMC2706586          DOI: 10.1124/mol.107.044230

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  40 in total

Review 1.  Isoprenoids as mediators of the biological effects of statins.

Authors:  James K Liao
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

2.  Cytokines induce nitric oxide-mediated mtDNA damage and apoptosis in oligodendrocytes. Protective role of targeting 8-oxoguanine glycosylase to mitochondria.

Authors:  Nadiya M Druzhyna; Sergyi I Musiyenko; Glenn L Wilson; Susan P LeDoux
Journal:  J Biol Chem       Date:  2005-04-04       Impact factor: 5.157

3.  Oligodendrocyte survival, loss and birth in lesions of chronic-stage multiple sclerosis.

Authors:  G Wolswijk
Journal:  Brain       Date:  2000-01       Impact factor: 13.501

4.  Selective vulnerability of late oligodendrocyte progenitors to hypoxia-ischemia.

Authors:  Stephen A Back; Byung Hee Han; Ning Ling Luo; Charlene A Chricton; Steve Xanthoudakis; John Tam; Kara L Arvin; David M Holtzman
Journal:  J Neurosci       Date:  2002-01-15       Impact factor: 6.167

5.  CNTF is a major protective factor in demyelinating CNS disease: a neurotrophic cytokine as modulator in neuroinflammation.

Authors:  Ralf A Linker; Mathias Mäurer; Stefanie Gaupp; Rudolf Martini; Bettina Holtmann; Ralf Giess; Peter Rieckmann; Hans Lassmann; Klaus V Toyka; Michael Sendtner; Ralf Gold
Journal:  Nat Med       Date:  2002-06       Impact factor: 53.440

Review 6.  Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy.

Authors:  H Lassmann; W Brück; C Lucchinetti
Journal:  Trends Mol Med       Date:  2001-03       Impact factor: 11.951

Review 7.  Why does remyelination fail in multiple sclerosis?

Authors:  Robin J M Franklin
Journal:  Nat Rev Neurosci       Date:  2002-09       Impact factor: 34.870

8.  LPS/IFN-gamma cytotoxicity in oligodendroglial cells: role of nitric oxide and protection by the anti-inflammatory cytokine IL-10.

Authors:  E Molina-Holgado; J M Vela; A Arévalo-Martín; C Guaza
Journal:  Eur J Neurosci       Date:  2001-02       Impact factor: 3.386

Review 9.  Stem cell repair of central nervous system injury.

Authors:  Qilin Cao; Richard L Benton; Scott R Whittemore
Journal:  J Neurosci Res       Date:  2002-06-01       Impact factor: 4.164

10.  Inhibition of Rho GTPases with protein prenyltransferase inhibitors prevents leukocyte recruitment to the central nervous system and attenuates clinical signs of disease in an animal model of multiple sclerosis.

Authors:  John Greenwood; Peter Adamson; Claire E Walters; Gareth Pryce; Deborah J R Hankey; Said M Sebti; Andrew D Hamilton; David Baker
Journal:  J Immunol       Date:  2002-04-15       Impact factor: 5.422

View more
  36 in total

Review 1.  Roles of NG2 glial cells in diseases of the central nervous system.

Authors:  Jian-Ping Xu; Jie Zhao; Shao Li
Journal:  Neurosci Bull       Date:  2011-12       Impact factor: 5.203

2.  Modulation of Rho-Rock signaling pathway protects oligodendrocytes against cytokine toxicity via PPAR-α-dependent mechanism.

Authors:  Ajaib S Paintlia; Manjeet K Paintlia; Avtar K Singh; Inderjit Singh
Journal:  Glia       Date:  2013-07-10       Impact factor: 7.452

3.  Effect of vitamin D3 intake on the onset of disease in a murine model of human Krabbe disease.

Authors:  Manjeet K Paintlia; Inderjit Singh; Avtar K Singh
Journal:  J Neurosci Res       Date:  2014-09-19       Impact factor: 4.164

4.  Novel role of Cdc42 and RalA GTPases in TNF-α mediated secretion of CCL2.

Authors:  Kelly A Langert; Cynthia L Pervan; Evan B Stubbs
Journal:  Small GTPases       Date:  2014-06-09

Review 5.  Peroxisome proliferator-activated receptor γ (PPARγ): A master gatekeeper in CNS injury and repair.

Authors:  Wei Cai; Tuo Yang; Huan Liu; Lijuan Han; Kai Zhang; Xiaoming Hu; Xuejing Zhang; Ke-Jie Yin; Yanqin Gao; Michael V L Bennett; Rehana K Leak; Jun Chen
Journal:  Prog Neurobiol       Date:  2017-10-12       Impact factor: 11.685

Review 6.  p75NTR and TROY: Uncharted Roles of Nogo Receptor Complex in Experimental Autoimmune Encephalomyelitis.

Authors:  Paschalis Theotokis; Nikolaos Grigoriadis
Journal:  Mol Neurobiol       Date:  2018-01-02       Impact factor: 5.590

7.  Activation of PPAR-γ and PTEN cascade participates in lovastatin-mediated accelerated differentiation of oligodendrocyte progenitor cells.

Authors:  Ajaib S Paintlia; Manjeet K Paintlia; Avtar K Singh; John K Orak; Inderjit Singh
Journal:  Glia       Date:  2010-11-01       Impact factor: 7.452

8.  P2Y12 receptor expression is a critical determinant of functional responsiveness to ATX's MORFO domain.

Authors:  Jameel Dennis; Magdalena K Morgan; Martin R Graf; Babette Fuss
Journal:  Purinergic Signal       Date:  2011-12-04       Impact factor: 3.765

9.  Combinatorial Effect of Metformin and Lovastatin Impedes T-cell Autoimmunity and Neurodegeneration in Experimental Autoimmune Encephalomyelitis.

Authors:  Ajaib S Paintlia; Sarumathi Mohan; Inderjit Singh
Journal:  J Clin Cell Immunol       Date:  2013-06-30

10.  Original Research: Atorvastatin prevents rat cardiomyocyte hypertrophy induced by parathyroid hormone 1-34 associated with the Ras-ERK signaling.

Authors:  Xiaogang Liu; Chunbo Zou; Chengyuan Yu; Rujuan Xie; Manshu Sui; Suhong Mu; Li Li; Shilei Zhao
Journal:  Exp Biol Med (Maywood)       Date:  2016-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.